

MERZ AESTHETICS®

## BOOTCAMP SERIES

**XEOMIN®**

IncobotulinumtoxinA

Science Technique  
& the Patient Discussion

**Full Prescribing Information and Medication Guide | Follow us on Instagram @XeominAesthetic**

Please see Important Safety Information, including **BOXED WARNING**, below.

# Xperience the Difference

## Double up on expertise: The Xeomin® Aesthetic Bootcamp

You're invited to a Xeomin exploration so expansive, we couldn't cover it all in one session! In this web-based meeting, over two evenings, we address the key topics essential to optimizing Xeomin in your practice.

### What you'll learn

#### Toxin 101

- Topline review of toxin science
- Detailed facial anatomy specific to toxin injections
- Technical and practical discussion of injection technique
- Best practices for reconstitution


#### The Xeomin Consultation

- Understanding the disposition and needs of today's patient
- Fine-tuning the patient consultation with Xeomin
- Insider tips on patient engagement and conversion
- Utilizing refreshed resources and effective tools
- Cultivating patient loyalty for mutual benefit

**September 18th  
8:00 PM EST**

**CLICK HERE TO REGISTER**

**Your meeting link will be sent to you the evening before the event.**



**XeominAesthetic.com  
@xeominaesthetic**

#### PLEASE SEE IMPORTANT SAFETY INFORMATION

##### INDICATIONS AND USAGE

XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines with corrugator and/or procerus muscle activity in adult patients.

##### IMPORTANT SAFETY INFORMATION

###### **WARNING: DISTANT SPREAD OF TOXIN EFFECT**

The effects of XEOMIN and botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties may be life threatening and there have been reports of death.

The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have these symptoms that would predispose them to these symptoms.

##### CONTRAINdications

Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur, XEOMIN injection, soft tissue edema, and dyspnea should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin immediately instilled or to any of the components in the formulation.

Use in patients with an infection at the injection site could lead to severe local or disseminated infection.

XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).

##### WARNINGS AND PRECAUTIONS

The changeable units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations or botulinum toxin products (anaphylaxis, serum sickness, further injection, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur, XEOMIN injection, soft tissue edema, and dyspnea should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin immediately instilled or to any of the components in the formulation.

Use in patients with an infection at the injection site could lead to severe local or disseminated infection.

XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).

##### ADVERSE REACTIONS

XEOMIN contains human serum albumin. Based on effective dose, bony supraorbital ridge.

The effects of XEOMIN may be potentiated by other botulinum toxin products at the same time or within several months of each other. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

##### IN PREGNANCY

There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women.

XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

##### PEDIATRIC USE

Safety and effectiveness of XEOMIN in patients less than 18 years of age have not been established.

**MERZ AESTHETICS®**

Copyright © 2022 Merz North America, Inc. All rights reserved. Xeomin is a registered trademark of Merz Pharma GmbH & Co. KGaA. US-XEA-2200097